|
47 Companies |
|
64 Products |
|
64 Products |
|
53 Mechanisms of Action |
|
2 Trials |
|
265 News |
|
| «123456» |
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Enrollment closed: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 27, 2016
P2, N=33, Active, not recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Active, not recruiting
- Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Enrollment open, Combination therapy: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 18, 2016
P2, N=45, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Suspended --> Recruiting
- cytarabine / Generic mfg.
Biomarker, Trial completion: S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=310, Completed, Sponsor: Southwest Oncology Group
Suspended --> Recruiting Active, not recruiting --> Completed
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial primary completion date: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Mar 10, 2016
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Jul 2017
- metformin / Generic mfg., cytarabine / Generic mfg.
Enrollment closed, Enrollment change: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) - Feb 24, 2016
P1, N=2, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Feb 2016 --> Jul 2017 Recruiting --> Active, not recruiting | N=28 --> 2
- Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Trial suspension, Combination therapy: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 4, 2016
P2, N=45, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=28 --> 2 Recruiting --> Suspended
- Ninlaro (ixazomib) / Takeda
Enrollment change, Trial termination, Trial primary completion date: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 26, 2016
P2, N=4, Terminated, Sponsor: Bruno C. Medeiros
Recruiting --> Suspended N=16 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Nov 2015; Regulatory
- Synribo (omacetaxine mepesuccinate) / Teva
Trial termination: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 15, 2016
P2, N=2, Terminated, Sponsor: Roswell Park Cancer Institute
N=16 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Nov 2015; Regulatory Active, not recruiting --> Terminated; Major revisions needed in study
- Trial completion, Enrollment change, Trial primary completion date: Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission (clinicaltrials.gov) - Dec 31, 2015
P2, N=263, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Terminated; Major revisions needed in study Recruiting --> Completed | N=200 --> 263 | Trial primary completion date: Dec 2013 --> Jul 2015
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date: S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 25, 2015
P3, N=784, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=200 --> 263 | Trial primary completion date: Dec 2013 --> Jul 2015 Trial primary completion date: Apr 2017 --> Jun 2018
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Dec 21, 2015
P2, N=14, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Apr 2017 --> Jun 2018 Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015
- cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2015
P2, N=134, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Completed | N=195 --> 134 | Trial primary completion date: Sep 2016 --> Dec 2015
- Synribo (omacetaxine mepesuccinate) / Teva
Enrollment closed, Enrollment change, Trial primary completion date: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 25, 2015
P2, N=2, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | N=195 --> 134 | Trial primary completion date: Sep 2016 --> Dec 2015 Recruiting --> Active, not recruiting | N=60 --> 2 | Trial primary completion date: Nov 2018 --> Nov 2015
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 16, 2015
P1, N=19, Recruiting, Sponsor: Bruno C. Medeiros
Recruiting --> Active, not recruiting | N=60 --> 2 | Trial primary completion date: Nov 2018 --> Nov 2015 Suspended --> Recruiting
- Ninlaro (ixazomib) / Takeda
Enrollment open: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 16, 2015
P2, N=16, Recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Recruiting Suspended --> Recruiting
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Enrollment open: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 16, 2015
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Recruiting Suspended --> Recruiting
- Enrollment open: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 15, 2015
P1, N=30, Recruiting, Sponsor: Stanford University
Suspended --> Recruiting Suspended --> Recruiting
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Trial primary completion date: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 10, 2015
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Suspended --> Recruiting Trial primary completion date: Jul 2015 --> Jul 2016
- | Zolinza (vorinostat) / Merck (MSD)
Enrollment closed, Trial primary completion date: S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 9, 2015
P3, N=784, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Apr 2017
- lithium carbonate ER / Generic mfg.
Enrollment closed, Trial primary completion date: Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 20, 2015
P1, N=24, Active, not recruiting, Sponsor: Paolo Caimi, MD
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Apr 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015
- decitabine / Generic mfg.
Trial primary completion date: Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 27, 2015
P2, N=546, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015 Trial primary completion date: Jan 2013 --> Jan 2011
- Trial termination: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 20, 2015
P1, N=13, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2013 --> Jan 2011 Active, not recruiting --> Terminated; Inadequate accrual rate
- Trial completion, Combination therapy: Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 14, 2015
P1, N=3, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Terminated; Inadequate accrual rate Active, not recruiting --> Completed
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial suspension: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P1, N=19, Suspended, Sponsor: Bruno C. Medeiros
Active, not recruiting --> Completed Recruiting --> Suspended
- Ninlaro (ixazomib) / Takeda
Trial suspension: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P2, N=16, Suspended, Sponsor: Bruno C. Medeiros
Recruiting --> Suspended Recruiting --> Suspended
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial suspension: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 13, 2015
P2, N=33, Suspended, Sponsor: Bruno C. Medeiros
Recruiting --> Suspended Recruiting --> Suspended
- Trial suspension: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2015
P1, N=30, Suspended, Sponsor: Stanford University
Recruiting --> Suspended Recruiting --> Suspended
- Trial completion, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 12, 2015
P2, N=44, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Suspended Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 9, 2015
P1, N=24, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Jul 21, 2015
P2, N=61, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial primary completion date: Jan 2014 --> Dec 2016
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Enrollment change, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Jul 10, 2015
P2, N=6, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jan 2014 --> Dec 2016 Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011
- | Zolinza (vorinostat) / Merck (MSD)
Enrollment open: S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 9, 2015
P3, N=784, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011 Suspended --> Recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 9, 2015
P2, N=92, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Active, not recruiting --> Completed
- ||||||| zosuquidar (LY335979) / Kanisa Pharma
Trial completion: Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia (clinicaltrials.gov) - Jun 24, 2015
P3, N=449, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (clinicaltrials.gov) - Jun 20, 2015
P2, N=4, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Lack of funding
- Enrollment closed, Trial primary completion date: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=15, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Terminated; Lack of funding Trial primary completion date: Apr 2016 --> Apr 2015 | Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial suspension: S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 11, 2015
P3, N=784, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2016 --> Apr 2015 | Recruiting --> Active, not recruiting Recruiting --> Suspended
- cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial initiation date, Trial primary completion date, Combination therapy: Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 11, 2015
P2, N=195, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Suspended Initiation date: Mar 1994 --> Sep 1994 | Trial primary completion date: Sep 2015 --> Sep 2016
- Enrollment change, Trial primary completion date: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - May 21, 2015
P1, N=13, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 1994 --> Sep 1994 | Trial primary completion date: Sep 2015 --> Sep 2016 N=18 --> 13 | Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - May 6, 2015
P=N/A, N=15, Recruiting, Sponsor: University of Washington
N=18 --> 13 | Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Apr 2015 --> Apr 2016
- Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Trial primary completion date, Combination therapy: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 29, 2015
P2, N=45, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: May 2015 --> May 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Apr 14, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Mar 2015 --> Sep 2015
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial completion, Enrollment change, Trial primary completion date: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=2, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Mar 2015 --> Sep 2015 Recruiting --> Completed | N=29 --> 2 | Trial primary completion date: Dec 2016 --> Jan 2015
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML (clinicaltrials.gov) - Mar 28, 2015
P3, N=637, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Completed | N=29 --> 2 | Trial primary completion date: Dec 2016 --> Jan 2015 Active, not recruiting --> Completed
- Enrollment change, Combination therapy: Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 19, 2015
P1, N=3, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=34 --> 3
- pravastatin / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change: Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=19, Completed, Sponsor: Fred Hutchinson Cancer Research Center
N=34 --> 3 Active, not recruiting --> Completed | N=50 --> 19
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 19, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed | N=50 --> 19 Trial primary completion date: Mar 2014 --> Mar 2015
- pravastatin / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Enrollment closed: Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- MK-2206 / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 7, 2015
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=43 --> 19 | Trial primary completion date: Oct 2012 --> Oct 2013
- MK-8776 / Merck (MSD)
Enrollment change: Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 6, 2015
P2, N=10, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=43 --> 19 | Trial primary completion date: Oct 2012 --> Oct 2013 N=52 --> 10